Literature DB >> 8680090

[Role of interleukin 6 in hepatocellular carcinoma].

M Malaguarnera1, I Di Fazio, A Laurino, M A Romeo, I Giugno, B A Trovato.   

Abstract

Interleukin 6 (IL-6) is a pleiotropic cytokine which possesses a broad spectrum of action in diverse pathological conditions. It is mainly produced and metabolised in the liver where it carries out one of its best known actions in the mediation of the acute phase response. We studied its behaviour in hepatocellular carcinoma to evaluate its clinical prognostic role. We determined serum IL-6 concentrations in 39 patients with hepatocarcinoma (27 males and 12 females) and 25 healthy controls (15 males and ten females). Our results showed a significant increase in serum IL-6 concentrations in hepatocarcinoma subjects compared with controls (P < 0.005) and an elevated positive correlation (r = 0.616) between IL-6 and size of the hepatocarcinoma. Our study demonstrated that IL-6 is able to influence hepatocarcinoma progression by acting as an autocrine tumoral growth factor and depleting immune surveillance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8680090

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  13 in total

Review 1.  Serum markers of hepatocellular carcinoma.

Authors:  Giulia Malaguarnera; Maria Giordano; Isabella Paladina; Massimiliano Berretta; Alessandro Cappellani; Mariano Malaguarnera
Journal:  Dig Dis Sci       Date:  2010-03-26       Impact factor: 3.199

2.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

3.  Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Fabio D'Antona; Ada-Maria Florena; Emanuele La Spada; Angela Terranova; Melchiorre Cervello; Natale D'Alessandro; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

4.  Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma.

Authors:  G Y Chau; C W Wu; W Y Lui; T J Chang; H L Kao; L H Wu; K L King; C C Loong; C Y Hsia; C W Chi
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

Review 5.  Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives.

Authors:  Hoda Elkhenany; Ahmed Shekshek; Mohamed Abdel-Daim; Nagwa El-Badri
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus.

Authors:  M Malaguarnera; I Di Fazio; M A Romeo; S Restuccia; A Laurino; B A Trovato
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

7.  Increased HCMV seroprevalence in patients with hepatocellular carcinoma.

Authors:  Quentin Lepiller; Manoj K Tripathy; Vincent Di Martino; Bernadette Kantelip; Georges Herbein
Journal:  Virol J       Date:  2011-10-27       Impact factor: 4.099

Review 8.  Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.

Authors:  Melchiorre Cervello; James A McCubrey; Antonella Cusimano; Nadia Lampiasi; Antonina Azzolina; Giuseppe Montalto
Journal:  Oncotarget       Date:  2012-03

9.  IL-6 upregulation contributes to the reduction of miR-26a expression in hepatocellular carcinoma cells.

Authors:  Yafei Zhang; Bicheng Zhang; Anran Zhang; Xiaohua Li; Jian Liu; Jie Zhao; Yong Zhao; Jianfei Gao; Dianchun Fang; Zhiguo Rao
Journal:  Braz J Med Biol Res       Date:  2012-09-25       Impact factor: 2.590

10.  Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients.

Authors:  Mohamed S Othman; Ahmed M Aref; Amal A Mohamed; Wesam A Ibrahim
Journal:  ISRN Hepatol       Date:  2013-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.